The oral spinal muscular atrophy (SMA) treatment ‘Evrysdi’ may be prescribed at general hospitals.

According to industry sources, Roche Korea’s SMA treatment Evrysdi (risdiplam) passed the drug committee (DC) reviews of several medical institutions including Seoul National University Hospital.

Evrysdi was first approved in Korea in November 2020 ‘to treat SMA in adults and children 2 months of age and older.’ In the US, its indication has recently been extended to cover infants less than 2 months of age.

As the first oral option introduced in the field of SMA, Evrysdi has the advantage of allowing customization according to age and weight.

However, its